(EXEL) Exelixis - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 12.605m USD | Total Return: 18.5% in 12m
Avg Turnover: 138M
EPS Trend: 96.1%
Qual. Beats: 0
Rev. Trend: 96.9%
Qual. Beats: 0
Warnings
Fakeout
Tailwinds
Confidence
Exelixis, Inc. is an oncology-focused biotechnology company specializing in the development and commercialization of small molecule and antibody-based therapies for difficult-to-treat cancers. The company’s core portfolio is built on cabozantinib, a multi-tyrosine kinase inhibitor marketed as CABOMETYX for advanced renal cell carcinoma and COMETRIQ for metastatic medullary thyroid cancer. The biotechnology sector typically requires high research and development reinvestment to maintain a competitive pipeline of patent-protected intellectual property.
The company maintains a diverse clinical pipeline featuring zanzalintinib, synthetic lethal targets for BRCA-mutated tumors, and several antibody-drug conjugates (ADCs). ADCs represent a growing class of precision medicine designed to deliver potent cytotoxic payloads directly to cancer cells while sparing healthy tissue. Exelixis supports its commercial reach through strategic licensing agreements with global pharmaceutical firms including Roche, Takeda, and Bristol-Myers Squibb.
Headquartered in Alameda, California, the firm operates primarily within the United States but generates international revenue through partnerships for products like MINNEBRO in Japan. Investors looking for deeper insights into these clinical assets should consult ValueRay for additional data. Exelixis continues to expand its oncology footprint through internal discovery and external business development activities.
- Cabometyx dominant market share in renal cell carcinoma drives core revenue growth
- Clinical trial results for zanzalintinib dictate long-term pipeline valuation and sentiment
- Patent litigation outcomes for cabozantinib create significant binary risk for investors
- Expansion into antibody-drug conjugates diversifies revenue beyond the mature tyrosine kinase portfolio
- Strategic collaborations and royalty streams from international partners impact net profit margins
| Net Income: 833.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.35 > 0.02 and ΔFCF/TA 8.12 > 1.0 |
| NWC/Revenue: 35.26% < 20% (prev 43.39%; Δ -8.12% < -1%) |
| CFO/TA 0.36 > 3% & CFO 924.7m > Net Income 833.4m |
| Net Debt (-607.7m) to EBITDA (998.7m): -0.61 < 3 |
| Current Ratio: 3.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (267.3m) vs 12m ago -7.24% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 87.48% > 50% (prev 81.03%; Δ 6.46% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.32 (Total Current Assets 1.21b - Total Current Liabilities 371.0m) / Total Assets 2.59b |
| B: -0.08 (Retained Earnings -215.8m / Total Assets 2.59b) |
| C: 0.36 (EBIT TTM 970.1m / Avg Total Assets 2.72b) |
| D: -0.33 (Book Value of Equity -216.0m / Total Liabilities 657.8m) |
| Altman-Z'' = 3.90 = AA |
| DSRI: 1.13 (Receivables 328.9m/281.6m, Revenue 2.38b/2.30b) |
| GMI: 1.00 (GM 96.44% / 96.78%) |
| AQI: 1.00 (AQ_t 0.39 / AQ_t-1 0.39) |
| SGI: 1.03 (Revenue 2.38b / 2.30b) |
| TATA: -0.04 (NI 833.4m - CFO 924.7m) / TA 2.59b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 50.48 with a total of 2,950,681 shares traded.
Over the past week, the price has changed by +1.67%,
over one month by +12.96%,
over three months by +14.57% and
over the past year by +18.50%.
Exelixis has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy EXEL.
- StrongBuy: 9
- Buy: 1
- Hold: 9
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 49.7 | -1.6% |
P/E Trailing = 16.606
P/E Forward = 15.7233
P/S = 5.3065
P/B = 6.4483
P/EG = 2.2685
Revenue TTM = 2.38b USD
EBIT TTM = 970.1m USD
EBITDA TTM = 998.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 169.5m USD (from shortLongTermDebtTotal, last quarter) (leases 169.5m already included)
Net Debt = -607.7m USD (calculated: Debt 169.5m - CCE 777.2m)
Enterprise Value = 12.0b USD (12.6b + Debt 169.5m - CCE 777.2m)
Interest Coverage Ratio = unknown (Ebit TTM 970.1m / Interest Expense TTM 0.0)
EV/FCF = 13.09x (Enterprise Value 12.0b / FCF TTM 916.4m)
FCF Yield = 7.64% (FCF TTM 916.4m / Enterprise Value 12.0b)
FCF Margin = 38.58% (FCF TTM 916.4m / Revenue TTM 2.38b)
Net Margin = 35.08% (Net Income TTM 833.4m / Revenue TTM 2.38b)
Gross Margin = unknown ((Revenue TTM 2.38b - Cost of Revenue TTM 84.5m) / Revenue TTM)
Tobins Q-Ratio = 4.63 (Enterprise Value 12.0b / Total Assets 2.59b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 169.5m)
Taxrate = 21.38% (57.2m / 267.7m)
NOPAT = 762.7m (EBIT 970.1m * (1 - 21.38%))
Current Ratio = 3.26 (Total Current Assets 1.21b / Total Current Liabilities 371.0m)
Debt / Equity = 0.09 (Debt 169.5m / totalStockholderEquity, last quarter 1.94b)
Debt / EBITDA = -0.61 (Net Debt -607.7m / EBITDA 998.7m)
Debt / FCF = -0.66 (Net Debt -607.7m / FCF TTM 916.4m)
Total Stockholder Equity = 2.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.69% (Net Income 833.4m / Total Assets 2.59b)
RoE = 36.42% (Net Income TTM 833.4m / Total Stockholder Equity 2.29b)
RoCE = 43.65% (EBIT 970.1m / Capital Employed (Total Assets 2.59b - Current Liab 371.0m))
RoIC = 50.25% (NOPAT 762.7m / Invested Capital 1.52b)
WACC = 8.00% (E(12.6b)/V(12.8b) * Re(8.11%) + D(169.5m)/V(12.8b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -6.77%
[DCF] Terminal Value 77.97% ; FCFF base≈858.7m ; Y1≈984.4m ; Y5≈1.45b
[DCF] Fair Price = 89.15 (EV 21.8b - Net Debt -607.7m = Equity 22.4b / Shares 251.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.10 | EPS CAGR: 118.3% | SUE: 0.64 | # QB: 0
Revenue Correlation: 96.92 | Revenue CAGR: 13.33% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.86 | Chg30d=+5.56% | Revisions=+57% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.90 | Chg30d=+3.27% | Revisions=+29% | Analysts=9
EPS current Year (2026-12-31): EPS=3.57 | Chg30d=+3.93% | Revisions=+47% | GrowthEPS=+15.9% | GrowthRev=+11.8%
EPS next Year (2027-12-31): EPS=4.05 | Chg30d=+3.02% | Revisions=+33% | GrowthEPS=+13.4% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: +57%